Precision Oncology Research in Glioblastoma: an Update

Glioblastoma is the most aggressive brain tumor in adults and is characterized by its extremely poor prognosis with a 5-year survival rate of less than 10%.
Since last year, QbD has been actively supporting Professor Frederik De Smet's research into glioblastoma after Pieter Van Vlierbeghe was diagnosed with glioblastoma (a close friend of our CEO Bart Van Acker).

With QbD's support, the LPCM (Laboratory for Precision Cancer Medicine - KU Leuven) in collaboration with Lab Normal and Malignant Hematopoiesis (UGent) is investigating the clinical potential of asparaginase, a therapeutic currently used to treat acute lymphoblastic leukemia, for the treatment of glioblastoma.

QbD invites you to a brief update on the status of precision oncology research in glioblastoma on May 9 at QbD’s HQ in Wilrijk.